visilizumab
mAbexperimental
Visilizumab is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease. — Wikipedia
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Apr 1, 2001 (NCT00006009)
Timeline
Indications
Mechanism of action
CD3E inhibitor
Non¿FcR-binding anti-CD3 monoclonal antibody (mAb) directed against the invariant CD3e chain of the TCR.
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVisilizumab ↗
- ChEMBLCHEMBL2108811 ↗
Also known as
- hum291
- hum291
- nuvion
- nuvion
- smart anti-cd3
- visilizumab
- visilizumab
- visilizumab
- visilizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04722952 | Phase 3 | May 1, 2021 | Soochow University |
| NCT00720629 | Phase 2 | Dec 1, 2007 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of South Florida |
| NCT00502294 | Phase 3 | Jul 13, 2007 | Facet Biotech, PDL BioPharma |
| NCT00279435 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2006 | Facet Biotech, PDL BioPharma |
| NCT00307827 | Phase 2 | Apr 1, 2006 | Abbott |
| NCT00279422 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2006 | Facet Biotech, PDL BioPharma |
| NCT00267722 | Phase 2 | Feb 1, 2005 | Facet Biotech, PDL BioPharma |
| NCT00267709 | Phase 2 | Feb 1, 2005 | Facet Biotech, PDL BioPharma |
| NCT00267306 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2004 | Facet Biotech, PDL BioPharma |
| NCT00032305 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2002 | Facet Biotech |
| NCT00032292 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2002 | Facet Biotech |
| NCT00032279 | Phase 2 | Mar 1, 2002 | Facet Biotech, University of Washington |
| NCT00006009 | Phase 1 | Apr 1, 2001 | National Cancer Institute (NCI), Stanford University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Facet Biotech | For profit | 9 | 8 | 2 | 2002 |
| PDL BioPharma | For profit | 6 | 0 | 2 | 2004 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2001 |
| Abbott | For profit | 1 | 1 | 1 | 2006 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2007 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2001 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2002 |
9 organizations
Page 1 / 1